Phillip G. Febbo, M.D.

Phillip G. Febbo, M.D., is Chief Scientific Officer and Chief Medical Officer at Veracyte. Dr. Febbo is a distinguished life sciences leader with more than 25 years of experience across academia and industry, and a proven track record of improving patient outcomes by driving adoption of molecular tests through evidence development, guideline inclusion, key opinion leader support, and commercialization.

Prior to joining Veracyte in 2023, Dr. Febbo served as Chief Medical Officer for Illumina where he built the medical team and led the successful strategy to engage clinical customers. Prior to that, he was Chief Medical Officer for Genomic Health, where he oversaw the development and expansion of the company’s test portfolio, including the evidence demonstrating clinical validity and clinical utility in order to drive reimbursement. Earlier in his career, Dr. Febbo was a professor of medicine and urology at the University of California, San Francisco Medical Center, and prior to that he was an associate professor of medicine and molecular genetics and microbiology at Duke University School of Medicine. He currently serves on the board of the Reagan Udall Foundation for the U.S. Food and Drug Administration (FDA) and was an independent director for Varian, Inc. prior to its acquisition by Siemens Healthineers.

Dr. Febbo holds a B.A. in Biology from Dartmouth College and earned his M.D. from the University of California, San Francisco. He completed his internal medicine residency at Brigham and Women's Hospital and his medical oncology fellowship at the Dana Farber Cancer Institute.